DiaSorin

Healthy Q2 and H1; resulting in consecutive guidance upgrade

04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."

PDF page sample
Pages
62
Language
English
Published on
04/08/22
Download
You may also be interested by these reports :
20/10/25
“Only when the tide goes out do you discover who’s been swimming naked.” This famous line from Warren Buffett fits well for the ...
20/10/25
Despite a significant downgrade in our estimates, our strong buy recommendation for Elekta remains unchanged. This is supported by ongoing ...
17/10/25
This quarter was strong, driven by the launch of new AI products. We were surprised by the very strong performance in North America and Europe. ...
17/10/25
Drägerwerk delivered solid preliminary Q3 2025 numbers. Revenue of €833m was up 10.1%, translating into a 370bps expansion in the EBIT margin to 6.8% ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO